Valneva (NASDAQ:VALN) Shares Gap Down – Should You Sell?

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN) gapped down before the market opened on Thursday. The stock had previously closed at $5.87, but opened at $5.61. Valneva shares last traded at $5.6550, with a volume of 6,142 shares changing hands.

Wall Street Analyst Weigh In

VALN has been the subject of several recent analyst reports. TD Cowen began coverage on Valneva in a research note on Tuesday, August 11th. They set a “buy” rating and a $12.00 target price for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Valneva in a report on Monday, September 14th. One investment analyst has rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Reduce” and a consensus target price of $9.30.

Valneva Stock Down 3.4%

The firm has a market cap of $538.03 million, a PE ratio of -2.69 and a beta of 1.53. The company has a quick ratio of 1.69, a current ratio of 2.16 and a debt-to-equity ratio of 2.04. The business has a 50-day moving average price of $6.27 and a two-hundred day moving average price of $5.87.

Valneva (NASDAQ:VALN) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.21). The firm had revenue of $39.37 million for the quarter, compared to analyst estimates of $44.17 million. Valneva had a negative return on equity of 153.20% and a negative net margin of 110.33%. On average, equities research analysts expect that Valneva SE Sponsored ADR will post -1.27 EPS for the current year.

About Valneva

Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France. The company develops, manufactures and commercializes vaccines intended to address infectious diseases with significant unmet medical needs, including travel-related illnesses, endemic diseases and emerging public-health threats.

Valneva’s marketed products include IXIARO, a vaccine for Japanese encephalitis, and DUKORAL, an oral vaccine used for protection against cholera and certain types of traveler’s diarrhea.